Drugs / HCR-188
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06845943 | Mar → Oct 2025 | obesity disorder | Helicore Biopharma, Inc. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCR-188 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06845943 ↗ |
| Route | Subcutaneous | “HCR-188 administered as subcutaneous injection(s)” NCT06845943 ↗ |